Claims for Patent: 7,279,469

Summary for Patent: 7,279,469

Title:	Diaminotriazoles useful as inhibitors of protein kinases
Abstract:	The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
Inventor(s):	Pierce; Albert C. (Cambridge, MA), Amost; Michael (North Andover, MA), Davies; Robert J. (Arlington, MA), Forster; Cornelia J. (Pelham, NH), Galullo; Vincent (South Grafton, MA), Grey, Jr.; Ronald (Cambridge, MA), Ledeboer; Mark (Acton, MA), Tian; Shi-Kai (Waltham, MA), Xu; Jinwang (Framingham, MA), Binch; Hayley (Harwell, GB), Ledford; Brian (Attleboro, MA), Messersmith; David (Somerville, MA), Nanthakumar; Suganthi (Newton, MA), Jayaraj; Andrew (Needham, MA), Henkel; Greg (Carlsbad, CA), Salituro; Francesco G. (Marlboro, MA), Wang; Jian (Newton, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:	10/715,111
Patent Claims:	1. A compound of formula II or II': ##STR01345## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is hydrogen; R.sup.2 is Ar.sup.1, wherein Ar.sup.1 is a phenyl group substituted with x independent occurrences of Q-R.sup.X, wherein x is 1-5; Q is a bond or is a C.sub.1-C.sub.6 alkylidene chain wherein up to two methylene units of Q are optionally replaced by --NR--, --S--, --O--, --CS--, --CO.sub.2--, --OCO--, --CO--, --COCO--, --CONR--, --NRCO--, --NRCO.sub.2--, --SO.sub.2NR--, --NRSO.sub.2--, --CONRNR--, --NRCONR--, --OCONR--, --NRNR--, --NRSO.sub.2NR--, --SO--, --SO.sub.2--, --PO--, --PO.sub.2--, or --POR--; and each occurrence of R.sup.x is independently R', halogen, NO.sub.2, CN, OR', SR', N(R').sub.2, NR'COR', NR'CONR'.sub.2, NR'CO.sub.2R', COR', CO.sub.2R', OCOR', CON(R').sub.2, OCON(R').sub.2, SOR', SO.sub.2R', SO.sub.2N(R').sub.2, NR'SO.sub.2R', NR'SO.sub.2N(R').sub.2, COCOR', or COCH.sub.2COR', wherein at least one Q-R.sup.X is not hydrogen; R.sup.3 is Ar.sup.2, wherein Ar.sup.2 is an optionally substituted aryl group selected from pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thiophenyl, oxazolyl, thiazolyl, oxadiazolyl, thiadiazolyl, or an 8-12 membered bicyclic ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein said aryl group is optionally substituted with y occurrences of Z-R.sup.Y; wherein y is 0-5, Z is a bond or is a C.sub.1-C.sub.6 alkylidene chain wherein up to two methylene units of Z are optionally replaced by --NR--, --S--, --O--, --CS--, --CO.sub.2--, --OCO--, --CO--, --COCO--, --CONR--, --NRCO--, --NRCO.sub.2--, --SO.sub.2NR--, --NRSO.sub.2--, --CONRNR--, --NRCONR--, --OCONR--, --NRNR--, --NRSO.sub.2NR--, --SO--, or --SO.sub.2--; and each occurrence of R.sup.Y is independently R', halogen, NO.sub.2, CN, OR', SR', N(R').sub.2, NR'COR', NR'CONR'.sub.2, NR'CO.sub.2R', COR', CO.sub.2R', OCOR', CON(R').sub.2, OCON(R').sub.2, SOR', SO.sub.2R', SO.sub.2N(R').sub.2, NR'SO.sub.2R', NR'SO.sub.2N(R').sub.2, COCOR', or COCH.sub.2COR'; and each occurrence of R is independently hydrogen or an optionally substituted C.sub.1-6 aliphatic group; and each occurrence of R' is independently hydrogen or an optionally substituted group selected from a C.sub.1-6 aliphatic group, a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R and R', two occurrences of R, or two occurrences of R', are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; provided that: a) when R.sup.3 is pyridyl, pyrimidinedione, then R.sup.2 is not phenyl simultaneously substituted with one occurrence of OMe in the meta position, and one occurrence of oxazole in the para position; or b) when R.sup.3 is unsubstituted pyrimidinyl, then R.sup.2 is not p-OMe substituted phenyl, p-OEt substituted phenyl, or o-OMe substituted phenyl. 2. The compound of claim 1, wherein said compound has the formula II-A-(i) or II-A-(i)': ##STR01346## wherein each of m and n is 0. 3. The compound of claim 2, wherein Ar.sup.2 is selected from one of the following groups: ##STR01347## ##STR01348## ##STR01349## ##STR01350## wherein any substitutable carbon or nitrogen atom is optionally substituted by ZR.sup.Y. 4. The compound of claim 2, wherein Ar is selected from one of the following groups: ##STR01351## wherein any substitutable carbon or nitrogen atom is optionally substituted by ZR.sup.Y. 5. The compound of claim 1, wherein Ar.sup.2 is optionally substituted 2-pyridyl, 2-thiazolyl, 2-pyrimidinyl, 6-pyrimidinyl, 4-pyridyl, benzothiazolyl, or 2-quinolinyl, and said compound has one of the structures II-F-(i), II-G-(i), II-G'-(i), II-H-(i)', II-I-(i), II-I'-(i), II-J-(i), II-F-(i)', II-G-(i)', II-G'-(i)', II-H-(i)', II-I-(i)', II-I'-(i)', or II-J-(i)': ##STR01352## ##STR01353## ##STR01354## ##STR01355## ##STR01356## ##STR01357## wherein n is 0. 6. The compound of claim 2, wherein Ar.sup.2 is pyridyl, pyrimidinyl, quinolinyl, or thiazolyl, each optionally substituted with 0-3 occurrences of ZR.sup.Y. 7. The compound of claim 6, wherein x is 1-3; y is 0-3; and each occurrence of QR.sup.X or ZR.sup.Y is independently R', halogen, CN, NO.sub.2, --N(R').sub.2, --CH.sub.2N(R').sub.2, --OR', --CH.sub.2OR', --SR', --CH.sub.2SR', --COOR', --NRCOR', --CON(R').sub.2, --SO.sub.2N(R').sub.2, --CONR(CH.sub.2).sub.2N(R').sub.2, --CONR(CH.sub.2).sub.3N(R').sub.2, --CONR(CH.sub.2).sub.4N(R').sub.2, --O(CH.sub.2).sub.2OR', --O(CH.sub.2).sub.3)R', --O(CH.sub.2).sub.4OR', --O(CH.sub.2).sub.2N(R').sub.2, --O(CH.sub.2).sub.3N(R').sub.2, or --O(CH.sub.2).sub.4N(R').sub.2. 8. The compound of claim 5, wherein x is 1-3; y is 0-3; and each occurrence of QR.sup.X or ZR.sup.Y is independently Cl, Br, F, CF.sub.3, Me, Et, CN, --COGH, --N(CH.sub.3).sub.2, --N(Et).sub.2, --N(iPr).sub.2, --O(CH.sub.2).sub.2OCH.sub.3, --CONH.sub.2, --COOCH.sub.3, --OH, --CH.sub.2OH, --NHCOCH.sub.3, --SO.sub.2NH.sub.2, methylenedioxy, ethylenedioxy, --O(CH.sub.2).sub.2N-morpholino, --O(CH.sub.2).sub.3N-morpholino, --O(CH.sub.2).sub.4N-morpholino, --O(CH.sub.2).sub.2N-piperazinyl, --O(CH.sub.2).sub.3N-piperizinyl, --O(CH.sub.2).sub.4N-piperizinyl, --NHCH(CH.sub.2OH)phenyl, --CONH(CH.sub.2).sub.2N-morpholino, --CONH(CH.sub.2).sub.2N-piperazinyl, --CONH(CH.sub.2).sub.3N-morpholino, --CONH(CH.sub.2).sub.3N-piperazinyl, --CONH(CH.sub.2).sub.4N-morpholino, --CONH(CH.sub.2).sub.4N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.2N-morpholino, --SO.sub.2NH(CH.sub.2).sub.2N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.3N-morpholino, --SO.sub.2NH(CH.sub.2).sub.3N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.4N-morpholino, --SO.sub.2NH(CH.sub.2).sub.4N-piperazinyl, where each of the foregoing phenyl, morpholino, piperazinyl, or piperidinyl groups is optionally substituted, or an optionally substituted group selected from C.sub.1-4 alkoxy, phenyl, phenyloxy, benzyl, piperidinyl, piperazinyl, morpholino, or benzyloxy. 9. The compound of claim 1, having one of the formulae: ##STR01358## ##STR01359## 10. The compound of claim 9, wherein x is 1-3; y is 0-3; and each occurrence of QR.sup.X or ZR.sup.Y is independently R', halogen, CN, NO.sub.2-N(R').sub.2, --CH.sub.2N(R').sub.2, --OR', --CH.sub.2OR', --SR', --CH.sub.2SR', --COOR', --NRCOR', --CON(R').sub.2, --SO.sub.2N(R').sub.2, --CONR(CH.sub.2).sub.2N(R').sub.2, --CONR(CH.sub.2).sub.3N(R').sub.2, --CONR(CH.sub.2).sub.4N(R',).sub.2, --O(CH.sub.2).sub.2OR', --O(CH.sub.2).sub.3OR', --O(CH.sub.2).sub.40R', --O(CH.sub.2).sub.2N(R').sub.2, --O(CH.sub.2).sub.3N(R').sub.2, or --O(CH.sub.2).sub.4N(R').sub.2. 11. The compound of claim 10, wherein QR.sup.X or ZR.sup.Y groups are each independently Cl, Br, F, CF.sub.3, Me, Et, CN, --COOH, --N(CH.sub.3).sub.2, --N(Et).sub.2, --N(iPr).sub.2, --O(CH.sub.2).sub.20CH.sub.3, --CONH.sub.2, --COOCH.sub.3, --OH, --CH.sub.2OH, --NHCOCH.sub.3, --SO.sub.2NH.sub.2, methylenedioxy, ethylenedioxy, --O(CH.sub.2).sub.2N-morpholino, --O(CH.sub.2).sub.3N-morpholino, --O(CH.sub.2).sub.4N-morpholino, --O(CH.sub.2).sub.2N-piperazinyl, --O(CH.sub.2).sub.3N-piperizinyl, --O(CH.sub.2).sub.4N-piperizinyl, --NHCH(CH.sub.2OH)phenyl, --CONH(CH.sub.2).sub.2N-morpholino, --CONH(CH.sub.2).sub.2N-piperazinyl, --CONH(CH.sub.2).sub.3N-morpholino, --CONH(CH.sub.2).sub.3N-piperazinyl, --CONH(CH.sub.2).sub.4N-morpholino, --CONH(CH.sub.2).sub.4N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.2N-morpholino, --SO.sub.2NH(CH.sub.2).sub.2N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.3N-morpholino, --SO.sub.2NH(CH.sub.2).sub.3N-piperazinyl, --SO.sub.2NH(CH.sub.2).sub.4N-morpholino, --SO.sub.2NH(CH.sub.2).sub.4N-piperazinyl, where each of the foregoing phenyl, morpholino, piperazinyl, or piperidinyl groups is optionally substituted, or an optionally substituted group selected from C.sub.1-4alkoxy, phenyl, phenyloxy, benzyl, piperidinyl, piperazinyl, morpholino, or benzyloxy. 12. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 13. The composition of claim 12, further comprising an additional therapeutic agent selected mechlorethamine, chlorambucil, cyclophosphamide, melphalan, ifosfamide, methotrexate, 6-mercaptopurine, 5-fluorouracil, cytarabile, gemcitabine, vinblastine, vincristine, vinorelbine, paclitaxel, etoposide, irinotecan, topotecan, doxorubicin, bleomycin, mitomycin, carmustine, lomustine, cisplatin, carboplatin, asparaginase, tamoxifen, leuprolide, flutamide, megestrol, imatinib mesylate, adriamycin, dexamethasone, cyclophosphamide, donepezil (Aricept.RTM.), rivastigmine (Excelon.RTM.)), L-DOPAlcarbidopa, entacapone, ropinrole, pramipexole, bromocriptine, pergolide, trihexephendyl, amantadine, glatiramer (Copaxone.RTM.), mitoxantrone, albuterol, montelukast (Singulair.RTM.), zyprexa, risperdal, seroquel, haloperidol, a corticosteroid, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide, sulfasalazine, cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, an interferon, cyclophosphamide, azathioprine, sulfasalazine, an acetylcholinesterase inhibitor, a monoamine oxidase inhibitor, an interferon, an anti-convulsant, an ion channel blocker, riluzole, a beta-blocker, an acetyl cholinesterase inhibitor, a diuretic, a nitrate, a calcium channel blocker, a statin, cholestyramine, or gamma globulin. 14. A method of inhibiting FLT-3 or c-KIT kinase activity in a biological sample in vitro selected from a cell culture, saliva, urine, feces, semen, tears, or extracts thereof, comprising the step of contacting said biological sample with: a) a composition according to claim 12; or b) a compound according to claim 1. 15. The compound of claim 1, wherein said compound is selected from the following: ##STR01360## ##STR01361## ##STR01362## ##STR01363## ##STR01364## ##STR01365## ##STR01366## ##STR01367## ##STR01368## ##STR01369## ##STR01370## ##STR01371## ##STR01372## ##STR01373## ##STR01374## ##STR01375## ##STR01376## ##STR01377## ##STR01378## ##STR01379## ##STR01380## ##STR01381## ##STR01382## ##STR01383## ##STR01384## ##STR01385## ##STR01386## ##STR01387## ##STR01388## ##STR01389## ##STR01390## ##STR01391## ##STR01392## ##STR01393## ##STR01394## ##STR01395## ##STR01396## ##STR01397## ##STR01398## ##STR01399## ##STR01400## ##STR01401## ##STR01402## ##STR01403## ##STR01404## ##STR01405## ##STR01406## ##STR01407## ##STR01408## ##STR01409## ##STR01410## ##STR01411## ##STR01412## ##STR01413## ##STR01414## ##STR01415## ##STR01416## ##STR01417## ##STR01418## ##STR01419## ##STR01420## ##STR01421## ##STR01422## ##STR01423## ##STR01424## ##STR01425## ##STR01426## ##STR01427## ##STR01428## ##STR01429## ##STR01430## ##STR01431## ##STR01432## ##STR01433## ##STR01434## ##STR01435## ##STR01436## ##STR01437## ##STR01438## ##STR01439## ##STR01440## ##STR01441## ##STR01442## ##STR01443## ##STR01444## ##STR01445## ##STR01446## ##STR01447## ##STR01448## ##STR01449## ##STR01450## ##STR01451## ##STR01452## ##STR01453## ##STR01454## ##STR01455## ##STR01456## ##STR01457## ##STR01458## ##STR01459## ##STR01460## ##STR01461## ##STR01462## ##STR01463## ##STR01464## ##STR01465## ##STR01466## ##STR01467## ##STR01468## ##STR01469## ##STR01470## ##STR01471## ##STR01472## ##STR01473## ##STR01474## ##STR01475## ##STR01476## ##STR01477## ##STR01478## ##STR01479## ##STR01480## ##STR01481## ##STR01482## ##STR01483## ##STR01484## ##STR01485## ##STR01486## ##STR01487## ##STR01488## ##STR01489## ##STR01490## ##STR01491## ##STR01492## ##STR01493## ##STR01494## ##STR01495## ##STR01496## ##STR01497## ##STR01498## ##STR01499## ##STR01500## ##STR01501## ##STR01502## ##STR01503## ##STR01504## ##STR01505## ##STR01506## ##STR01507## ##STR01508## ##STR01509## ##STR01510## ##STR01511## ##STR01512## ##STR01513## ##STR01514## ##STR01515## ##STR01516## ##STR01517## ##STR01518## ##STR01519## ##STR01520## ##STR01521## ##STR01522## ##STR01523## ##STR01524## ##STR01525## ##STR01526##

Details for Patent 7,279,469

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2022-11-15